State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia
Top Cited Papers
- 11 March 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 49 (4), 591-605
- https://doi.org/10.1007/s15010-021-01602-z
Abstract
Background The incidence of secondary pulmonary infections is not well described in hospitalized COVID-19 patients. Understanding the incidence of secondary pulmonary infections and the associated bacterial and fungal microorganisms identified can improve patient outcomes. Objective This narrative review aims to determine the incidence of secondary bacterial and fungal pulmonary infections in hospitalized COVID-19 patients, and describe the bacterial and fungal microorganisms identified. Method We perform a literature search and select articles with confirmed diagnoses of secondary bacterial and fungal pulmonary infections that occur 48 h after admission, using respiratory tract cultures in hospitalized adult COVID-19 patients. We exclude articles involving co-infections defined as infections diagnosed at the time of admission by non-SARS-CoV-2 viruses, bacteria, and fungal microorganisms. Results The incidence of secondary pulmonary infections is low at 16% (4.8–42.8%) for bacterial infections and lower for fungal infections at 6.3% (0.9–33.3%) in hospitalized COVID-19 patients. Secondary pulmonary infections are predominantly seen in critically ill hospitalized COVID-19 patients. The most common bacterial microorganisms identified in the respiratory tract cultures are Pseudomonas aeruginosa, Klebsiella species, Staphylococcus aureus, Escherichia coli, and Stenotrophomonas maltophilia. Aspergillus fumigatus is the most common microorganism identified to cause secondary fungal pulmonary infections. Other rare opportunistic infection reported such as PJP is mostly confined to small case series and case reports. The overall time to diagnose secondary bacterial and fungal pulmonary infections is 10 days (2–21 days) from initial hospitalization and 9 days (4–18 days) after ICU admission. The use of antibiotics is high at 60–100% involving the studies included in our review. Conclusion The widespread use of empirical antibiotics during the current pandemic may contribute to the development of multidrug-resistant microorganisms, and antimicrobial stewardship programs are required for minimizing and de-escalating antibiotics. Due to the variation in definition across most studies, a large, well-designed study is required to determine the incidence, risk factors, and outcomes of secondary pulmonary infections in hospitalized COVID-19 patients.Keywords
This publication has 94 references indexed in Scilit:
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States*Critical Care Medicine, 2012
- Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial PneumoniaClinical Infectious Diseases, 2010
- Multiple organ infection and the pathogenesis of SARSThe Journal of Experimental Medicine, 2005
- Increase in Methicillin-Resistant Staphylococcus aureus Acquisition Rate and Change in Pathogen Pattern Associated with an Outbreak of Severe Acute Respiratory SyndromeClinical Infectious Diseases, 2004
- Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)Journal of Clinical Pathology, 2004
- Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysisBMJ, 2003
- A Novel Coronavirus Associated with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003